KURA ONCOLOGY INC. - COMMON STOCK

Kura Oncology to Participate in Upcoming Investor Conferences

01 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

23 фев 2023 16:03:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

16 фев 2023 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

09 фев 2023 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

07 фев 2023 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

24 янв 2023 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

10 дек 2022 10:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Host Investor Event on December 10, 2022

01 дек 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Two Upcoming Investor Conferences

22 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

03 ноя 2022 09:01:13 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2022 Financial Results

03 ноя 2022 07:30:01 Источник Nasdaq GlobeNewswire

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

03 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Two Upcoming Investor Conferences

02 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2022 Financial Results  

27 окт 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

26 окт 2022 07:30:01 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

01 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2022 Financial Results

03 авг 2022 16:03:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

02 авг 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2022 Financial Results

27 июл 2022 07:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

26 май 2022 07:30:00 Источник Nasdaq GlobeNewswire